Press release

Senzime expands production capacity based on joint call from European and American Anesthesia Associations and increasing market demand

In the June edition of the leading scientific journal Anesthesiology, the two major anesthesiology societies globally (ASA – American Society of Anesthesiologists and ESAIC – European Society of Anaesthesiology and Intensive Care) published a joint statement calling on healthcare systems to systematically follow recommendations outlined in the recently issued guidelines. Importantly, the statement provides a united front that encourages the healthcare systems to introduce quantitative neuromuscular monitoring in all places where patients undergo anesthesia and receive muscle relaxants.

Senzime's TetraGraph, and its TetraSens disposable electrode, with its digital technology and leading algorithms, are used for monitoring these patients and were specifically developed to meet and exceed parameters called out in the clinical guidelines that were published independently by the ASA and ESAIC – and that have now been emphasized jointly.

The driving forces in the market have resulted in increased shipments of TetraSens during the first half of 2023 of more than 170% compared to the same period in 2022. Senzime thus surpasses 130,000 delivered TetraSens electrodes since 2019 (excluding one-off stocking orders to distributor in South Korea), of which more than 50% (about 70,000) have been delivered in the last 12 months. This development can be seen in a diagram enclosed as an appendix on the company’s website.

To meet market demand, Senzime is now expanding its delivery capacity at the company's production facility in Uppsala. The company's assessment is that the delivery capacity needs to exceed 500 TetraGraph systems for the second half of 2023. TetraSens production is secured with key subcontractors to cover the currently installed base, as well as the new systems planned for roll-out in the second half of 2023.

“There is no doubt that the recent joint statement from the leading anesthesia societies regarding neuromuscular blockade monitoring has made this an even higher priority for physicians and hospital administrators around the globe. Based on ongoing evaluations and estimated order intake, our production facilities are currently scaling up to meet delivery volumes in excess of 500 TetraGraph monitors in the second half of 2023. With these deliveries Senzime will pass two major milestones, having achieved an installed base of 2,000 TetraGraphs and having sold more than 100,000 sensors in the year 2023. It is very gratifying to see that monitor sales and most importantly new and recurring sensor deliveries are growing as they are – proving our consumable-based business model. June 2023 was a milestone as the first single month in which Senzime shipped more than 10,000 TetraSens", says Philip Siberg, CEO of Senzime.

Senzime's quarterly report for the second quarter of the year will be published on 24 August 2023.

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.